protein

Recombinant Human uPAR / CD87 Protein (His tag)

MBS2546010

0.1 mg

405 USD

Recombinant Protein

Recombinant Human uPAR / CD87 Protein (His tag)

[uPAR / CD87]

[CD87;U-PAR;UPAR;URKR]

[urokinase plasminogen activator surface receptor isoform 2; Urokinase plasminogen activator surface receptor; urokinase plasminogen activator surface receptor; plasminogen activator, urokinase receptor; Monocyte activation antigen Mo3; CD_antigen: CD87]

[uPAR / CD87]

[PLAUR; PLAUR; CD87; UPAR; URKR; U-PAR; MO3; UPAR; U-PAR; uPAR]

HEK293 Cells

>98 % as determined by reducing SDS-PAGE

Lyophilized from sterile PBS, pH 7.4, 5% Trehalose, 5% Mannitol, 0.01% Tween-80.

Storage: Lyophilized proteins are stable for up to 12 months when stored at -20 to -80 degree C. Reconstituted protein solution can be stored at 4-8 degree C for 2-7 days. Aliquots of reconstituted samples are stable at < -20 degree C for 3 months. Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

SDS-PAGE

Species: Human. Sequence: Met 1-Arg 303. Tag: Carboxy-His. Endotoxin: < 1.0 EU per ug of the protein as determined by the LAL method.

Bio activity: Measured by its binding ability in a functional ELISA. Immobilized human uPARat 5 ug/ml (100 ul/well) can bind biotinylated human UPA with a linear ranger of 40-1000 ng/ml. Reconstitution: It is recommended that sterile water(800ul) be added to the vial to prepare a stock solution of 0.25mg/mL. Concentration is measured by UV-Vis.

Urokinase plasminogen activator (uPA) and/or its receptor (uPAR) are essential for metastasis, and overexpression of these molecules is strongly correlated with poor prognosis in a variety of malignant tumours. uPAR and uPA levels in both resected tumor tissue and plasma are of independent prognostic significance for patient survival in several types of human cancer. This system has classically been thought to drive tumor progression by mediating directed extracellular proteolysis on the surface of migrating or invading cells, and intervening with this proteolysis by targeting uPAR has been proposed to represent a novel approach for inhibiting tumor progression. uPAR, also known as PLAUR or CD87, has been implicated in the growth, metastasis, and angiogenesis of several solid and hemotologic malignancies. uPAR is a highly glycosylated, 55-60kDa integral membrane protein linked to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. It is part of a cell surface system that also consists of the serine protease uPA and several specific inhibitors (plasminogen activator inhibitors 1 and 2). Additionally, the analysis of CD87 (urokinasetype plasminogen activator receptor - uPAR) expression has a potential role in the diagnostic or prognostic work-up of several hematological malignancies, particularly acute leukemia and multiple myeloma.

53829379

NP_001005376.1

NM_001005376.2

Q03405-1

Mol Mass: 32.8 kDa. AP Mol Mass: 48 kDa

Arf6 Downstream Pathway (138038); Attachment Of GPI Anchor To UPAR Pathway (106239); Complement And Coagulation Cascades Pathway (198880); Complement And Coagulation Cascades Pathway (83073); Complement And Coagulation Cascades Pathway (484); Dissolution Of Fibrin Clot Pathway (106061); FGF Signaling Pathway (137989); Hemostasis Pathway (106028); Metabolism Of Proteins Pathway (106230); Post-translational Modification: Synthesis Of GPI-anchored Proteins Pathway (106236)

This gene encodes the receptor for urokinase plasminogen activator and, given its role in localizing and promoting plasmin formation, likely influences many normal and pathological processes related to cell-surface plasminogen activation and localized degradation of the extracellular matrix. It binds both the proprotein and mature forms of urokinase plasminogen activator and permits the activation of the receptor-bound pro-enzyme by plasmin. The protein lacks transmembrane or cytoplasmic domains and may be anchored to the plasma membrane by a glycosyl-phosphatidylinositol (GPI) moiety following cleavage of the nascent polypeptide near its carboxy-terminus. However, a soluble protein is also produced in some cell types. Alternative splicing results in multiple transcript variants encoding different isoforms. The proprotein experiences several post-translational cleavage reactions that have not yet been fully defined. [provided by RefSeq, Jul 2008]

uPAR: Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form. Monomer (Probable). Interacts with MRC2. Interacts (via the UPAR/Ly6 domains) with SRPX2. Expressed in neurons of the rolandic area of the brain. Expressed in the brain. 3 isoforms of the human protein are produced by alternative splicing. Protein type: Membrane protein, GPI anchor; Motility/polarity/chemotaxis; Receptor, misc. Chromosomal Location of Human Ortholog: 19q13.31. Cellular Component: endoplasmic reticulum lumen; endoplasmic reticulum membrane; extrinsic to membrane; focal adhesion; plasma membrane. Molecular Function: enzyme binding; protein binding; protein domain specific binding; receptor binding; U-plasminogen activator receptor activity. Biological Process: attachment of GPI anchor to protein; chemotaxis; fibrinolysis; negative regulation of apoptosis; positive regulation of DNA binding; positive regulation of epidermal growth factor receptor signaling pathway; positive regulation of protein amino acid phosphorylation; signal transduction

0.1 mg

405 USD

0.2 mg

635